Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thrombocytosis 1Thrombocythemia, Essential 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Diseases 1Neuroblastoma 1Myeloproliferative Disorders 1Medulloblastoma 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Diseases 1Glioma 1Carcinoma 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1Astrocytoma 1

Interventions

Gemcitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sonidegib 1Irinotecan 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Diseases × sonidegib × Clear all
NCT01431794 2020-01-22

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Terminated
23 enrolled 10 charts
Gastrointestinal

Carcinoma, Pancreatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡